Pro-Pharmaceuticals' Executives Contribute to New Book ''Carbohydrate Drug Design'' Published by American Chemical Society
"Pro-Pharmaceuticals is pioneering a paradigm shift in the way new drugs are designed by advancing Glycoscience," said David Platt, Ph.D., Chief Executive Officer, Pro-Pharmaceuticals. "We believe our expertise in developing nanotechnology carbohydrate-based compounds offers numerous opportunities to advance treatment of cancer, liver, infectious, cardiovascular and inflammatory diseases."
“We believe our expertise in developing nanotechnology carbohydrate-based compounds offers numerous opportunities to advance treatment of cancer, liver, infectious, cardiovascular and inflammatory diseases.”
Contributing to the book was Dr. David Platt; Anatole Klyosov, Ph.D., D.Sc., Chief Scientist, Pro-Pharmaceuticals; Eliezer Zomer, Executive Vice President of Manufacturing & Product Development, Pro-Pharmaceuticals, and Zbigniew J. Witczak, a member of Pro-Pharmaceuticals Scientific Advisory Board, Associate Professor at the Nesbitt School of Pharmacy, Wilkes University and former chair of the ACS Division of Carbohydrate Chemistry.
The book was published by the American Chemical Society (ACS) as part of their Symposium Series which was first published in 1974. Some of the book's contents were presented by Pro-Pharmaceuticals during the 2004 Carbohydrate Drug Design Symposium at the 227th American Chemical Society Annual Meeting in Anaheim, California. Sponsored by Pro-Pharmaceuticals, the Symposium was organized by Anatole A. Klyosov, and chaired by David Platt. During the Symposium, Eliezer Zomer and Zbigniew J. Witczak made presentations.
DAVANAT(R), the Company's lead product candidate, is a proprietary nanotechnology polysaccharide polymer comprised of mannose and galactose carbohydrates in a CARBOSOME(TM) formation that enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) on cancer cells.
Phase III Colorectal Cancer Trial
The Company initiated a Europe-based Phase III clinical trial for second line treatment of patients with metastatic colorectal cancer. The trial is recruiting clinical sites in the European Union (EU) and countries outside of the EU following regulatory and ethics approval in each country. This study is a multi-center, randomized clinical trial to evaluate the safety and efficacy of DAVANAT(R) with 5-FU and leucovorin in combination with irinotecan or oxaliplatin. The Company expects to begin patient enrollment this quarter.
Phase II Cholangiocarcinoma Trial
The Company initiated a U.S.-based Phase II study of its lead carbohydrate compound DAVANAT(R) with 5-FU for first line treatment of patients with biliary carcinoma (cancer associated with the bile duct). The Company expects to begin patient enrollment this quarter. Cholangiocarcinoma may represent an opportunity for orphan drug status approval.
Pro-Pharmaceuticals, Inc. - Advancing Drugs Through Glycoscience(R)
Pro-Pharmaceuticals is a development stage company engaged in the discovery, development and commercialization of nanotechnology carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, infectious, cardiovascular and inflammatory diseases. Initially, the product pipeline is principally focused on increasing the efficacy and decreasing the toxicity of approved chemotherapy drugs. The Company has been conducting clinical and pre-clinical studies with its lead nanotechnology product candidate, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (AVASTIN(R)). Results show that DAVANAT(R) exhibits a broad spectrum of activity with tested drugs. Founded in 2000, the Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.
FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential products; uncertainties associated with pre-clinical and clinical trials of our product candidates; our limited experience in product development and expected dependence on potential licensees and collaborators for commercial manufacturing, sales, distribution and marketing of our potential products; possible development by competitors of competing products and technologies; lack of assurance regarding patent and other protection of our proprietary technology; compliance with and change of government regulation of our activities, facilities and personnel; uncertainties as to the extent of reimbursement for our potential products by government and private health insurers; our dependence on key personnel; our history of operating losses and accumulated deficit; and economic conditions related to the biotechnology and biopharmaceutical industry. We cannot assure you that we have identified all the factors that create uncertainties. Readers should not place undue reliance on forward-looking statements.
More information about those risks and uncertainties is contained and discussed in the "Management Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" sections of the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this news release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.
DAVANAT and Advancing Drugs Through Glycoscience are registered trademarks of Pro-Pharmaceuticals. CARBOSOME is a trademark of Pro-Pharmaceuticals. AVASTIN is a trademark of Genentech, Inc.